| Budget Amount *help |
¥2,400,000 (Direct Cost: ¥2,400,000)
Fiscal Year 1995: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1994: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1993: ¥800,000 (Direct Cost: ¥800,000)
|
|---|
| Research Abstract |
Transarterial emboliztion (TAE) is widely spred, and utilized for hepatocellular carcinoma (HCC) , in this country. This treatment achieved relative desirable efficacy, even in comparison between antitumorous treatments. This treatment has outstanding merits, such as, easy capture of antitumorous agent distribution in tissue in uninvasive inspection of CT as Lipiodol Ultarafluide (Lipiodol) density. On the model of this TAE,we developed a new drug delivery system by embolic emulsion utitlzed for malignant neoplasms.
Additional water-soluble contrast material stabilizes homogenized state of Lipiodol/antitumorous agent solution, such as ACNU.Furthermore, Glyceol, Poloxamer and D-Mannitol (Mannitol) makes this mixture a stable emulsion. In vivo, intravascular administration of these emulsion can cause pulmonary embolism, viseral embolism, in rabbits, which is certified histologically. In vitro visking examination and visceral concentration measurement reveal gradual diffusion of this antitumorous agent from these emulsions.
In the result of this investigation, therapeutic utility of these drug-delivering embolic emulsion is indicated. One of these emulsion conteining Mannitol (Mizonokuchi-Emulsion) is especially expected to generate continuous antitumorous effect for malignant brain tumors.
|
